Original news and analysis on international IP policy
Delinkage of research and development costs from medicines prices could "vastly expand" access to medicines by drastically dropping costs of the knowledge component of health products, innovative medicines R&D facility UNITAID says in a new report.
The now-familiar item of intellectual property and innovation is on the agenda for next week’s regular meeting of the intellectual property committee of the World Trade Organization. This time under the item, a range of developed countries have proposed to discuss education and diffusion, and Switzerland has put forward a paper on nurturing a culture of innovation.
The United States has spent over a decade trying to rein in so-called “patent trolls.” Nevertheless, a recent study suggests that patent trolls are a bigger problem than ever.
Re:Route, a mapping tool that lays out the research and development (R&D) landscape of innovation and financing for medicines, has been launched by the Universities Allied for Essential Medicines (UAEM). It is a one-stop place for the alternative biomedical research and development landscape.
The United States worked hard over the last five years to reduce patent infringement suits. Congress enacted patent reform, the courts handed down important anti-patentee rulings, and the US Patent and Trademark Office began a campaign of energetically rejecting patents and patent claims. Despite all this, from 2014 to 2015, new patent infringement suits increased 18 percent and the number of defendants sued for patent infringement increased 21 percent. What went wrong?
The well-worn phrase “no man is an island” may reflect a fundamental truth about the human condition, but it also provides wisdom into how to protect your company against patent trolls, writes Tim Wilson.
In the fight against antimicrobial resistance, members of the European Parliament’s Environment and Public Health Committee have advocated banning collective and preventive antibiotic treatment of animals, and supported measures to stimulate research into new antibiotics, including longer data protection.
Priorities for the pharmaceutical industry in 2016 are antimicrobial resistance and the quest for new antibiotics, the strengthening of regulatory systems to facilitate access to drugs, and work on non-communicable diseases, such as diabetes and cancer, according to the head of an international pharmaceutical industry group.
The World Intellectual Property Organization, a specialized agency of the United Nations, was unique among Geneva-based UN agencies for offering views at both recent meetings of the UN High-Level Panel on Access to Medicines held in Geneva and New York this month. Now WIPO has come under criticism from public health advocates for the views it gave.
Russian Health Minister Veronika Skvortsova said today that two “highly effective” vaccines against Ebola have been developed over the course of 15 months in Russia. The combined vaccine GamEvac-Combi was presented during a briefing, with the two scientists who developed it, who own the intellectual property rights on the vaccines in Russia.
The United Nations High-Level Panel on Access to Medicines has announced that the deadline for the submission of stakeholders’ contributions has been extended to 28 February 2016. The panel also lifted restrictions on the number of contributions authors can submit.
In an update on research and development against the Zika virus, the World Health Organization today said several companies are working on diagnostic tools, and two candidate vaccines are being considered. Discussions are ongoing with countries to encourage sharing of samples of the virus with the WHO, and leading organisations and scientific journals signed a declaration yesterday on the sharing of data for public health emergencies.